• 1
    Wen PY,Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep 2004; 4: 21827.
  • 2
    Holladay FP,Heitz T,Chen YL,Chiga M,Wood GW. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 1992; 31: 52833.
  • 3
    Velders MP,Schreiber H,Kast WM. Active immunization against cancer cells: impediments and advances. Semin Oncol 1998; 25: 697706.
  • 4
    de Vries TJ,Fourkour A,Wobbes T,Verkroost G,Ruiter DJ,van Muijen GN. Heterogeneous expression of immunotherapy candidate proteins gp100. MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997; 57: 32239.
  • 5
    Jager E,Ringhoffer M,Karbach J,Arand M,Oesch F,Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 4706.
  • 6
    Lee KH,Panelli MC,Kim CJ,Riker AI,Bettinotti MP,Roden MM,Fetsch P,Abati A,Rosenberg SA,Marincola FM. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998; 161: 418394.
  • 7
    Kaplan JM,Yu Q,Piraino ST,Pennington SE,Shankara S,Woodworth LA,Roberts BL. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999; 163: 699707.
  • 8
    Hsu SC,Chargelegue D,Obeid OE,Steward MW. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J Gen Virol 1999; 80 (Part 6): 14015.
  • 9
    Suhrbier A. Multi-epitope DNA vaccines. Immunol Cell Biol 1997; 75: 4028.
  • 10
    Ueda R,Iizuka Y,Yoshida K,Kawase T,Kawakami Y,Toda M. Identification of a human glioma antigen. SOX6, recognized by patients'sera. Oncogene 2004; 23: 14207.
  • 11
    Iizuka Y,Kojima H,Kobata T,Kawase T,Kawakami Y,Toda M. Identification of a glioma antigen. GARC-1, using cytotoxic. T lymphocytes induced by. HSV cancer vaccine. Int J Cancer 2006; 118: 9429.
  • 12
    Lefebvre V,Li P,de Crombrugghe B. A new long form of Sox5 (L-Sox5). Sox6 and. Sox9 are coexpressed in chondrogenesis and cooperatively activate the type. II. Collagen gene. Embo J 1998; 17: 571833.
  • 13
    Aulwurm S,Wischhusen J,Friese M,Borst J,Weller M. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 2006; 118: 172835.
  • 14
    Horton HM,Anderson D,Hernandez P,Barnhart KM,Norman JA,Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α. Proc Natl Acad Sci USA 1999; 96: 15538.
  • 15
    Lin KY,Guarnieri FG,Staveley-O'Carroll KF,Levitsky HI,August JT,Pardoll DM,Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 216.
  • 16
    Cohen-Barak O,Yi Z,Hagiwara N,Monzen K,Komuro I,Brilliant MH. Sox6 regulation of cardiac myocyte development. Nucleic Acids Res 2003; 31: 59418.
  • 17
    Ueda R,Yoshida K,Kawakami Y,Kawase T,Toda M. Expression of a transcriptional factor. SOX6, in human gliomas. Brain Tumor Pathol 2004; 21: 358.
  • 18
    Donnelly JJ,Wahren B,Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175: 6339.
  • 19
    Kirk CJ,Hartigan-O'Connor D,Nickoloff BJ,Chamberlain JS,Giedlin M,Aukerman L,Mule JJ. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001; 61: 206270.
  • 20
    Miller PW,Sharma S,Stolina M,Chen K,Zhu L,Paul RW,Dubinett SM. Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther 1998; 5: 3809.
  • 21
    Sharma S,Miller PW,Stolina M,Zhu L,Huang M,Paul RW,Dubinett SM. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 1997; 4: 136170.
  • 22
    Miller PW,Sharma S,Stolina M,Butterfield LH,Luo J,Lin Y,Dohadwala M,Batra RK,Wu L,Economou JS,Dubinett SM. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000; 11: 5365.
  • 23
    Munger K,Phelps WC,Bubb V,Howley PM,Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63: 441721.
  • 24
    Scheel JR,Ray J,Gage FH,Barlow C. Quantitative analysis of gene expression in living adult neural stem cells by gene trapping. Nat Methods 2005; 2: 36370.
  • 25
    Ueda R,Yoshida K,Kawakami Y,Kawase T,Toda M. Immunohistochemical analysis of SOX6 expression in human brain tumors. Brain Tumor Pathol 2004; 21: 11720.
  • 26
    Curcio C,Di Carlo E,Clynes R,Smyth MJ,Boggio K,Quaglino E,Spadaro M,Colombo MP,Amici A,Lollini PL,Musiani P,Forni G. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003; 111: 116170.
  • 27
    Qin H,Zhou C,Wang D,Ma W,Liang X,Lin C,Zhang Y,Zhang S. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology 2006; 117: 41930.
  • 28
    Murray JS. How the MHC selects Th1/Th2 immunity. Immunol Today 1998; 19: 15763.
  • 29
    Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 2636.
  • 30
    Hu HM,Winter H,Urba WJ,Fox BA. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 2000; 165: 424653.
  • 31
    Toes RE,Ossendorp F,Offringa R,Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189: 7536.